Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine.
Animals
Female
Glycine
/ analogs & derivatives
Male
Medically Unexplained Symptoms
Morphine
/ adverse effects
Morphine Dependence
/ drug therapy
Naloxone
/ toxicity
Narcotic Antagonists
/ toxicity
Nausea
/ chemically induced
Oleic Acids
/ pharmacology
Rats
Rats, Sprague-Dawley
Shrews
Substance Withdrawal Syndrome
/ drug therapy
Acute naloxone-precipitated morphine withdrawal
CB1
Gaping
N-oleoylglycine
Nausea
PPARα
Rats
Somatic MWD
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
17
06
2019
accepted:
30
09
2019
pubmed:
13
11
2019
medline:
5
8
2020
entrez:
13
11
2019
Statut:
ppublish
Résumé
Acute naloxone-precipitated morphine withdrawal (MWD) produces a conditioned place aversion (CPA) in rats even after one or two exposures to high-dose (20 mg/kg, sc) morphine followed 24-h later by naloxone (1 mg/kg, sc). However, the somatic withdrawal reactions produced by acute naloxone-precipitated MWD in rats have not been investigated. A recently discovered fatty acid amide, N-oleoylglycine (OlGly), which has been suggested to act as a fatty acid amide hydrolase (FAAH) inhibitor and as a peroxisome proliferator-activated receptor alpha (PPARα) agonist, was previously shown to interfere with a naloxone-precipitated MWD-induced CPA in rats. The aims of these studies were to examine the somatic withdrawal responses produced by acute naloxone-precipitated MWD and determine whether OlGly can also interfere with these responses. Here, we report that following two exposures to morphine (20 mg/kg, sc) each followed by naloxone (1 mg/kg, sc) 24 h later, rats display nausea-like somatic reactions of lying flattened on belly, abdominal contractions and diarrhea, and display increased mouthing movements and loss of body weight. OlGly (5 mg/kg, ip) interfered with naloxone-precipitated MWD-induced abdominal contractions, lying on belly, diarrhea and mouthing movements in male Sprague-Dawley rats, by both a cannabinoid 1 (CB These results suggest that the aversive effects of acute naloxone-precipitated MWD reflect nausea, which is suppressed by OlGly.
Identifiants
pubmed: 31712968
doi: 10.1007/s00213-019-05373-2
pii: 10.1007/s00213-019-05373-2
doi:
Substances chimiques
N-oleoylglycine
0
Narcotic Antagonists
0
Oleic Acids
0
Naloxone
36B82AMQ7N
Morphine
76I7G6D29C
Glycine
TE7660XO1C
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
375-384Subventions
Organisme : Natural Sciences and Engineering Research Council of Canada
ID : 03629
Organisme : Institute of Neurosciences, Mental Health and Addiction
ID : 388239
Références
Neuropsychopharmacology. 2006 Jan;31(1):171-7
pubmed: 15956992
Brain Res. 1978 Mar 24;143(2):263-79
pubmed: 630409
Neuroscience. 1990;37(3):767-73
pubmed: 2247222
Neuropharmacology. 2016 Mar;102:92-102
pubmed: 26541329
Pharmacol Biochem Behav. 1997 Dec;58(4):1003-8
pubmed: 9408206
J Pharmacol Exp Ther. 1977 Apr;201(1):44-54
pubmed: 557543
Neuropharmacology. 2019 Apr;148:320-331
pubmed: 29567093
Physiol Behav. 1992 Nov;52(5):895-9
pubmed: 1336599
J Pharmacol Exp Ther. 1964 Dec;146:385-94
pubmed: 14254334
Neuropharmacology. 2019 Sep 1;155:142-149
pubmed: 31145905
Science. 2007 Oct 26;318(5850):655-8
pubmed: 17962567
Pharmacol Biochem Behav. 2002 May;72(1-2):87-92
pubmed: 11900773
Clin Pharmacol Ther. 1995 Mar;57(3):270-80
pubmed: 7697945
Br J Pharmacol. 2017 Nov;174(21):3837-3847
pubmed: 28805944
J Pharmacol Exp Ther. 2011 Oct;339(1):173-85
pubmed: 21719468
Psychopharmacology (Berl). 2014 Nov;231(22):4291-300
pubmed: 24770676
Life Sci. 1982 Oct 11;31(15):1531-40
pubmed: 6890614
Psychopharmacology (Berl). 2004 Jan;171(2):156-61
pubmed: 13680081
Physiol Behav. 2012 Feb 1;105(3):856-60
pubmed: 22056540
Pharmacol Biochem Behav. 1992 Mar;41(3):559-65
pubmed: 1584835
Psychopharmacology (Berl). 2019 Sep;236(9):2623-2633
pubmed: 30993360
Pharmacol Biochem Behav. 1990 Jun;36(2):393-9
pubmed: 2356213
Psychopharmacology (Berl). 2015 Oct;232(20):3841-8
pubmed: 26297326
Br J Pharmacol. 2010 Sep;161(2):336-49
pubmed: 20735419
Pharmacol Biochem Behav. 1998 Nov;61(3):331-3
pubmed: 9768568
Eur J Pharmacol. 2014 Jan 5;722:122-33
pubmed: 24157975
Psychopharmacology (Berl). 1989;98(4):530-4
pubmed: 2505294
Neuropsychopharmacology. 2016 Jun;41(7):1865-73
pubmed: 26647976
Psychopharmacology (Berl). 2015 Feb;232(3):583-93
pubmed: 25085768
Pharmacopsychiatry. 2009 May;42 Suppl 1:S32-41
pubmed: 19434554
Pharmacol Biochem Behav. 1991 Nov;40(3):471-8
pubmed: 1666911